Patents by Inventor Alan Whitehead
Alan Whitehead has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11884683Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: GrantFiled: May 31, 2019Date of Patent: January 30, 2024Assignee: Merck Sharp & Dohme LLCInventors: Tao Yu, Alan Whitehead, Yili Chen, Chunrui Sun, Zhiyong Hu, Kake Zhao, Ronald M. Kim, John A. McCauley
-
Publication number: 20210309671Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, where-in R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: ApplicationFiled: May 31, 2019Publication date: October 7, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Tao YU, Alan WHITEHEAD, Yili CHEN, Chunrui SUN, Zhiyong HU, Kake ZHAO, Ronald M. KIM, John A. McCAULEY
-
Publication number: 20210115044Abstract: The present invention relates to Tricyclic Heterocycle Compounds of Formula (I): (I) and pharmaceutically acceptable salts or prodrug thereof, wherein R1, R2, R3, R4, R5, R6 and n are as defined herein. The present invention also relates to compositions comprising at least one Tricyclic Heterocycle Compound, and methods of using the Tricyclic Heterocycle Compounds for treating or preventing HIV infection in a subject.Type: ApplicationFiled: April 22, 2019Publication date: April 22, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Tao Yu, James M. Apgar, Alan Whitehead, Yonglian Zhang, Zhiyong Hu, Valerie W. Shurtleff, John A. McCauley, Izzat T. Raheem
-
Patent number: 10786488Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.Type: GrantFiled: January 23, 2018Date of Patent: September 29, 2020Assignee: MERCK SHARP & DOHME CORP.Inventors: Tao Yu, John A. McCauley, Alan Whitehead, James M. Apgar, Izzat T. Raheem, Guizhen Dong, Sherman T. Waddell, Hong Li
-
Patent number: 10780092Abstract: The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceuticals for this purpose.Type: GrantFiled: May 11, 2017Date of Patent: September 22, 2020Assignee: Merck Sharp & Dohme Corp.Inventors: Alan Whitehead, Olga Ornoski, Subharekha Raghavan, Raphaelle Berger, Joie Garfunkle, Zhiqiang Yang, Gang Ji, Falong Jiang, Jianmin Fu
-
Publication number: 20190365727Abstract: The present invention relates to Substituted Quinolizine Derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1 is as defined herein. The present invention also relates to compositions comprising at least one Substituted Quinolizine Derivative, and methods of using the Substituted Quinolizine Derivatives for treating or preventing HIV infection in a subject.Type: ApplicationFiled: January 23, 2018Publication date: December 5, 2019Applicant: MERCK SHARP & DOHME CORP.Inventors: Tao Yu, John A. McCauley, Alan Whitehead, James M. Apgar, Izzat T. Raheem, Guizhen Dong, Sherman T. Waddell, Hong Li
-
Publication number: 20190307753Abstract: The invention provides certain fused pyrazine compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, R1, R3, R4a, R5a, R5b, R6, and the subscript t are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases or disorders which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and disorders and for preparing pharmaceutical s for this purpose.Type: ApplicationFiled: May 11, 2017Publication date: October 10, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Alan Whitehead, Olga Ornoski, Subharekha Raghavan, Raphaelle Berger, Joie Garfunkle, Zhiqiang Yang, Gang JI, Falong Jiang, Jianmin Fu
-
Patent number: 10428076Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.Type: GrantFiled: June 27, 2018Date of Patent: October 1, 2019Assignee: Merck Sharp & Dohme Corp.Inventors: Raphaelle Berger, Yi-Heng Chen, Guoqing Li, Joie Garfunkle, Hong-Dong Li, Shouwu Miao, Subharekha Raghavan, Cameron J. Smith, John Stelmach, Alan Whitehead, Rui Zhang, Yong Zhang, Jianmin Fu, Gang Ji, Falong Jiang
-
Patent number: 10433217Abstract: A method and apparatus for redirecting a wireless communication unit (113) from a LTE cell to a neighboring 3G or 2G cell for the purposes of performing a procedure which is available in the 2G or 3G cell but not available in the LTE cell includes the provision of an additional LTE access point (109) within the coverage area of an LTE macrocell. The additional LTE access point (109) is arranged to capture a wireless communication unit (113) which is camped onto the LTE macrocell and redirect it to a 3G/2G cell irrespective of whether or not a better service may be provided in the 2G/3G cell. The invention has application to presence detection where collection of wireless communication units' and subscribers' IDs for such a purpose is possible in 3G and 2G cells but not in LTE cells.Type: GrantFiled: February 19, 2015Date of Patent: October 1, 2019Assignee: ip.access LimitedInventors: Christopher Edward John Kilgour, Nicholas Dougall Johnson, Neil Philip Piercy, James Edward Brereton Harrow, Alan Whitehead, David Charles Brock
-
Publication number: 20180305366Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: June 27, 2018Publication date: October 25, 2018Applicant: Merck Sharp & Dohme Corp.Inventors: Raphaelle Berger, Yi-Heng Chen, Guoqing Li, Joie Garfunkle, Hong-Dong Li, Shouwu Miao, Subharekha Raghavan, Cameron J. Smith, John Stelmach, Alan Whitehead, Rui Zhang, Yong Zhang, Jianmin Fu, Gang Ji, Falong Jiang
-
Patent number: 10030027Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.Type: GrantFiled: December 20, 2016Date of Patent: July 24, 2018Assignee: Merck Sharp & Dohme Corp.Inventors: Raphaelle Berger, Yi-Heng Chen, Guoqing Li, Joie Garfunkle, Hong-Dong Li, Shouwu Miao, Subharekha Raghavan, Cameron J. Smith, John Stelmach, Alan Whitehead, Rui Zhang, Yong Zhang, Jianmin Fu, Gang Ji, Falong Jiang
-
Patent number: 9783552Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 5, 2014Date of Patent: October 10, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Xiaoqing Han, Alan Whitehead, Subharekha Raghavan, Timothy A. Cernak, Spencer Dreher, Jonathan Groeper, Jian Guo, Yong Zhang
-
Publication number: 20170174693Abstract: The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R1, R2, R4, Ra, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate (“cGMP”), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.Type: ApplicationFiled: December 20, 2016Publication date: June 22, 2017Inventors: Raphaelle Berger, Yi-Heng Chen, Guoqing Li, Joie Garfunkle, Hong-Dong Li, Shouwu Miao, Subharekha Raghavan, Cameron J. Smith, John Stelmach, Alan Whitehead, Rui Zhang, Yong Zhang, Jianmin Fu, Gang Ji, Falong Jiang
-
Patent number: 9611278Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.Type: GrantFiled: December 5, 2014Date of Patent: April 4, 2017Assignee: Merck Sharp & Dohme Corp.Inventors: Xiaoqing Han, Alan Whitehead, Subharekha Raghavan, Jonathan Groeper, Jian Guo, Yong Zhang
-
Publication number: 20170013518Abstract: A method and apparatus for redirecting a wireless communication unit (113) from a LTE cell to a neighbouring 3G or 2G cell for the purposes of performing a procedure which is available in the 2G or 3G cell but not available in the LTE cell includes the provision of an additional LTE access point (109) within the coverage area of an LTE macrocell. The additional LTE access point (109) is arranged to capture a wireless communication unit (113) which is camped onto the LTE macrocell and redirect it to a 3G/2G cell irrespective of whether or not a better service may be provided in the 2G/3G cell. The invention has application to presence detection where collection of wireless communication units' and subscribers' IDs for such a purpose is possible in 3G and 2G cells but not in LTE cells.Type: ApplicationFiled: February 19, 2015Publication date: January 12, 2017Inventors: Christopher Edward John KILGOUR, Nicholas Dougall JOHNSON, Neil Philip PIERCY, James Edward Brereton HARROW, Alan WHITEHEAD, David Charles BROCK
-
Publication number: 20160304537Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 5, 2014Publication date: October 20, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Xiaoqing Han, Alan Whitehead, Subharekha Raghavan, Timothy A. Cernak, Spencer Dreher, Jonathan Groeper, Jian Guo, Yong Zhang
-
Publication number: 20160304536Abstract: A compound of Formula I or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula I or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: December 5, 2014Publication date: October 20, 2016Applicant: Merck Sharp & Dohme Corp.Inventors: Xiaoqing Han, Alan Whitehead, Subharekha Raghavan, Jonathan Groeper, Jian Guo, Yong Zhang
-
Patent number: 9365574Abstract: A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 24, 2011Date of Patent: June 14, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Subharekha Raghavan, John E. Stelmach, Cameron J. Smith, Hong Li, Alan Whitehead, Sherman T. Waddell, Yi-Heng Chen, Shouwu Miao, Olga A. Ornoski, Joie Garfunkle, Xibin Liao, Jiang Chang, Xiaoqing Han, Jian Guo, Jonathan A. Groeper, Linda L. Brockunier, Keith Rosauer, Emma R. Parmee
-
Patent number: 9231953Abstract: A network management system for managing communications in a cellular communication network comprising an access point operably coupled to an access controller. The network management system comprises an access controller configuration logic module arranged to configure the access controller with configuration information. The network management system further comprises an access point configuration logic module arranged to configure the access point with configuration information comprising, at least in part, configuration information intended for the access controller.Type: GrantFiled: July 18, 2014Date of Patent: January 5, 2016Assignees: CISCO TECHNOLOGY, INC., IP.ACCESS LIMITEDInventors: Joshua B. Littlefield, Anton Okmyanskiy, Archie Hensley, Edward Haynes, Ian McPherson, David Neil, Alan Whitehead
-
Publication number: 20140329501Abstract: A network management system for managing communications in a cellular communication network comprising an access point operably coupled to an access controller. The network management system comprises an access controller configuration logic module arranged to configure the access controller with configuration information. The network management system further comprises an access point configuration logic module arranged to configure the access point with configuration information comprising, at least in part, configuration information intended for the access controller.Type: ApplicationFiled: July 18, 2014Publication date: November 6, 2014Inventors: Joshua B. Littlefield, Anton Okmyanskiy, Archie Hensley, Edward Haynes, Ian McPherson, David Neil, Alan Whitehead